Fareva opens aerosol plant as part of $40m drug and OTC business investment

By Gareth Macdonald

- Last updated on GMT

iSotck/Paperkites
iSotck/Paperkites

Related tags Drug Pharmacology Pharmaceutical drug

Fareva Group has set up an aerosol manufacturing facility at its site in Richmond, Virginia as part of a $40m (€37m) investment in its drug, OTC medicine and beauty care business.

The plant has capacity to make 100 million aerosols cans a year according to Fareva, which said it plans to hire 80 to 100 people. The next phase of the project will see the firm invest a further $20m to set up four additional manufacturing lines.

Fareva bought the Richmond site from Pfizer in 2011​. At present, it makes topical drugs, over the counter medicines - including the cough treatment Robitussin (guaifenesin) - and various consumer products for the North American market.

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars